Clinical recommendations for correction of carbohydrate metabolism and sugar reducing therapy in patients with type 2 diabetes and chronic renal disease


DOI: https://dx.doi.org/10.18565/therapy.2019.2.8-13

NADEEVA R.A., SIGITOVA O.N., KIM T.Yu., KAMASHEVA G.R., KISELYOVA T.A.

Kazan medical University of the Ministry of Healthcare of Russia
Patients with kidney damage occupy an important place due to the significant prevalence in the population, reduced quality of life, high patient mortality and significant costs at the end- stage renal disease. Compensation of carbohydrate metabolism plays a key role in preventing the development and slowing the progression of chronic kidney disease (CKD) in diabetic patients. However, the target levels of compensation for carbohydrate metabolism may vary in patients at different stages of CKD and depend on the associated complications. In patients with CKD, the choice of hypoglycemic drugs depends on the pharmacodynamic characteristics of the drugs, their associated metabolic effects and side effects.
Keywords: glycemic compensation, hypoglycemic drugs, diabetes mellitus, glomerular filtration rate, chronic kidney disease
Read entire article

Literature


  1. Schernthaner G., Mogensen C.E., Schernthaner G.H. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab. Vasc. Dis. Res. 2014; 11(5): 306–23.

  2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (8 выпуск). Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. Сахарный диабет. 2017; 20(1S): 1–121.

  3. Сахарный диабет: острые и хронические осложнения. Под ред. И.И. Дедова, М.В. Шестаковой. М.: Медицинское информационное агентство, 2011. 480 с.

  4. U.S. Renal Data System, USRDS 2012 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012.

  5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329(14): 977–86.

  6. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003; 290(16): 2159–67.

  7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837–53.

  8. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358(24): 2560–72.

  9. Клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом. Российская ассоциация эндокринологов. М., 2015. Сайт https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/rec_hbp_pri_cd_2015_1.pdf

  10. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am. J. Kidney. Dis. 2012; 60(5): 850–86.

  11. Дедов И.И., Шестакова М.В., Галстян Г.Р., Григорян О.Р., Есаян М.Р., Калашников В.Ю. и соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. Сахарный диабет. 2015; 18(1): 1–112.

  12. Transcript for FDA’s Media Briefing: Guidance Document – diabetes mellitus, evaluating cardiovascular risk and new anti-diabetic therapies to treat type II вiabetes. Moderator: Karen Riley. December 17, 2008. Available from: http://www. fda.gov/ downloads/NewsEvents/ Newsroom/MediaTranscripts/ ucm121231.pdf.

  13. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabet. Care. 2012; 35(6): 1364–79.

  14. Heaf J.G., van Biesen W. Metformin and chronic renal impairment: a story of choices and ugly ducklings. Clin. Diabet. 2011; 29(3): 97–101.

  15. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2010(4): CD002967.

  16. Шамхалова М.Ш., Ярек-Мартынова И.Я., Трубицына Н.П., Шестакова М.В. Особенности сахароснижающей терапии у больных сахарным диабетом и хронической болезнью почек. Сахарный диабет. 2013; (3): 97–102.

  17. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007; 356(24): 2457–71.

  18. Kanjanabuch T., Ma L.J., Chen J., Pozzi A., Guan Y., Mundel P. et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int. 2007; 71(12): 1232–39.

  19. Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzalez E., Davies M.J. et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabet. Obes. Metab. 2008; 10(7): 545–55.

  20. Kothny W., Shao Q., Groop P.H., Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabet. Obes. Metab. 2012; 14(11): 1032–39.

  21. Nowicki M., Rychlik I., Haller H., Warren M.L., Suchower L., Gause-Nilsson I. et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabet. Obes. Metab. 2011; 13(6): 523–32.

  22. McGill J.B., Sloan L., Newman J., Patel S., Sauce C., von Eynatten M. et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabet. Care. 2013; 36(2): 237–44.

  23. Шестакова Е.А. Выбор второй линии терапии у пациентов с сахарным диабетом 2 типа: активация метаболической памяти. Сахарный диабет. 2017; 20(5): 356–62.

  24. Корбут А.И., Климонтов В.В. Терапия, основанная на инкретинах: почечные эффекты. Сахарный диабет. 2016; 19(1): 53–63.

  25. Wanner C., Inzucchi S.E., Lachin J.M. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 2016; 375(4): 323–34.

  26. Neal B., Perkovic V., Mahaffey K.W. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017; 377: 644–57.

  27. Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015; 373(22): 2117–28.

  28. Currie C.J., Poole C.D., Gale E.A. The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52(9): 1766–77.

  29. Defronzo R.A. Is insulin resistance atherogenic? Possible mechanisms. Atheroscler. Suppl. 2006; 7(4): 11–15.

  30. Nkondi Mbadi A.N., Longo-Mbenza B., Mvitu Muaka M., Mbungu F.S., Lemogoum D. Relationship between pulse pressure, visual impairement and severity of diabetic retinopathy in subSaharan Africa. Mali Med. 2009; 24(3): 17–21.

  31. Hashimoto J., Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. Hypertension. 2011; 58(5): 839–46.

  32. Ramakrishna V., Jailkhani R. Oxidative stress in noninsulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008; 45(1): 41–46.

  33. Козиолова Н.А., Чернявина А.И., Полянская Е.А. Выбор сахароснижающих препаратов у больных сахарным диабетом 2-го типа очень высокого сердечно-сосудистого риска (часть 1). Артериальная гипертензия. 2016; 22(4): 330–48.


About the Autors

Rosalia A. Nadeeva, PhD, associate professor of the Department of general practice No 1 of Kazan State medical University of the Ministry of Healthcare of Russia. Address: 420012, Kazan, 49 Butlerova Str. Tel./fax: +7 (843) 231-21-39. E-mail: rosa.nadeeva@gmail.com
Olga N. Sigitova, MD, professor, Head of the Department of general practice No 1 of Kazan State medical University of the Ministry of Healthcare of Russia. Address: 420012, Kazan, 49 Butlerova Str. Tel./fax: 8 (843) 231-21-39; tel.: +7 (917) 396-24-17. E-mail: osigit@rambler.ru
TaisiaYu. Kim, assistant professor of the Department of general practice No 1 of Kazan State medical University of the Ministry of Healthcare of Russia. Address: 420012, Kazan, 49 Butlerova Str. Tel./fax: 8 (843) 231-21-39. E-mail: tais_ariana@mail.ru
Gulnara R. Kamasheva, PhD, associate professor of the Department of general practice No 1 of Kazan State medical University of the Ministry of Healthcare of Russia. Address: 420012, Kazan, 49 Butlerova Str. Tel./fax: +7 (843) 231-21-39.
Tatiana A. Kiselyova, PhD, associate professor of the Department of endocrinology of Kazan State medical University of the Ministry of Healthcare of Russia. Address: 420012, Kazan, 49 Butlerova Str. Tel./fax: +7 (843) 231-21-39.


Similar Articles

Back to Content

Бионика Медиа